Abstract
Automatic seizure onset zone (SOZ) localization using interictal electrocorticogram (ECoG) improves the diagnosis and treatment of patients with medically refractory epilepsy. This study aimed to investigate the characteristics of phase-amplitude coupling (PAC) extracted from interictal ECoG and the feasibility of PAC served as a promising biomarker for SOZ identification. We employed the mean vector length modulation index approach on the 20-s ECoG window to calculate PAC features between low-frequency rhythms (0.5–24 Hz) and high frequency oscillations (HFOs) (80–560 Hz). We used statistical measures to test the significant difference in PAC between SOZ and non-seizure onset zone (NSOZ). To overcome the drawback of handcraft feature engineering, we established novel machine learning models to automatically learn the characteristics of PAC features obtained and classify them to identify SOZ. Besides, to conquer the imbalance of datasets, we introduced novel feature-wise/class-wise re-weighting strategies in conjunction with classifiers. In addition, we proposed the time-series nest cross-validation to provide more accurate and unbiased evaluations for this model. Seven patients with focal cortical dysplasia were included in this study. The experiment results not only illustrate that the significant coupling at band pairs of slow waves and HFOs exists in the SOZ when compared with the NSOZ but also indicate the effectiveness of PAC features and the proposed models with better classification performance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was fully supported by JST CREST (Grant No. JPMJCR1784).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Juntendo University Hospital gave ethical approval for this work; Ethics committee of Tokyo University of Agriculture and Technology gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.